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Abstract: A series of N-alkyl-3-(alkylamino)pyrazine-2-carboxamides and their N-alkyl-3-
chloropyrazine-2-carboxamide precursors were prepared. All compounds were 
characterized by analytical methods and tested for antimicrobial and antiviral activity. The 
antimycobacterial MIC values against Mycobacterium tuberculosis H37Rv of the most 
effective compounds, 3-(hexylamino)-, 3-(heptylamino)- and 3-(octylamino)-N-methyl-
pyrazine-2-carboxamides 14‒16, was 25 μg/mL. The compounds inhibited photosystem 2 
photosynthetic electron transport (PET) in spinach chloroplasts. This activity was strongly 
connected with the lipophilicity of the compounds. For effective PET inhibition longer alkyl 
chains in the 3-(alkylamino) substituent in the N-alkyl-3-(alkylamino)pyrazine-2-
carboxamide molecule were more favourable than two shorter alkyl chains. 
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1. Introduction 
Pyrazines are symmetrical heterocyclic aromatic organic compounds. Pyrazine is a weaker base than 
pyridine, pyridazine and pyrimidine. Pyrazine derivatives occur in many natural sources and can be 
synthesized chemically or biologically. In animals and plants, they are considered to be alert signal 
molecules, functioning as deterrents or attractants depending on the circumstances without having 
harmful or beneficial effect themselves. Pyrazines contribute to many aromas and flavours of heated 
foods such as beef products, toasted barley, cocoa, coffee, peanuts, popcorn, potato chips, rye crisp bread 
and roasted filberts, as well as in fresh foods like tomatoes, peas, green bell peppers, asparagus, kohlrabi 
and dairy products. The pyrazine moiety is an important part of many clinically used drugs, including 
anticancer, diuretic [1], antidiabetic, antithrombotic, antidepressants or anti-infective (antituberculotics, 
bactericides and fungicides) agents, and offers many possibilities in drug development [2–4]. 
Tuberculosis (TB) remains a serious global problem and the need for new drugs is still actual [5–7]. 
One of the most important drugs for TB treatment is pyrazinamide (PZA), which belongs to the  
first-line drugs for TB treatment and has been used extensively since 1980s. PZA has an excellent 
sterilizing effect on semi-dormant tubercle bacilli and, when used in combination with rifampicin, helps 
in shortening the duration of treatment [8]. One of the mechanisms of action is competitive inhibition of 
NADPH binding to Mycobacterium tuberculosis Fatty Acid Synthase I. This enzyme is devoted to the 
synthesis of common fatty acids and of specific mycolic acids, which constitute the major lipid 
component of the envelope and form the external mycomembrane. 5-Chloropyrazine-2-carboxamide 
analogues act as well as PZA [9,10]. 5-(Alkylamino)pyrazine-2-carboxamides and  
6-(alkylamino)pyrazine-2-carboxamides prepared previously by Servusová et al. [11], showed  
an interesting in vitro whole cell antimycobacterial activity. Based on these results we decided to prepare 
a series of 3-(alkylamino)pyrazine-2-carboxamides, to evaluate the importance of positional isomerism 
in these derivatives. 
Several herbicides acting as photosynthesis inhibitors (acylanilides, thioacylanilides, phenylcarbamates, 
ureas, etc.) have (thio)carbamoyl group, -NHCO- or -NHCS-, in their molecules [12–14]. Some 
commercially available herbicides act by reversible binding to photosystem 2 (PS2), a membrane-protein 
complex in the thylakoid membranes which catalyses the oxidation of water and the reduction of 
plastoquinone [15] and thereby inhibit photosynthetic electron transport (PET). Experimental studies 
have established that many PS 2 herbicides bind non-covalently to a 32 kDa protein in the PS2 complex 
and inhibit electron transfer between primary electron acceptor—quinone QA and the secondary electron 
acceptor—quinone QB on the reducing side of PS2 [16]. Numerous PS2 herbicides contain hydrophobic 
components as well as a flat polar component. The function of the hydrophobic components is to increase 
the lipid solubility of the entire herbicide molecule and to fit the hydrophobic surface of the herbicide 
binding site and it is assumed that the flat polar component binds electrostatically at a highly polar 
protein site [17]. Using EPR spectroscopy it was shown that tyrosine radicals TyrZ and TyrD which are 
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situated in D1 and D2 proteins on the donor side of PS2 interacted with some organic compounds, e.g., 
substituted benzanilides [18] or substituted 2,6-disubstituted pyridine-4-thiocarboxamides [19] or 
anilides of pyrazine-2-carboxylic acids [14,20] and due to this interaction interruption of the 
photosynthetic electron transport occurred. 
This study is focused on preparation of alkyl substituted derivatives of PZA. More specifically, it 
deals with the length of the alkylamino chain in position 3 and its influence on biological effects in 
comparison with previously evaluated 5- and 6-alkylamino isomers. Antimycobacterial activity of all 
prepared compounds was determined and compounds were evaluated also for inhibition of photosynthetic 
electron transport (PET) in spinach (Spinacia oleracea L.) chloroplasts. The structure-activity relationships 
between the chemical structure and in vitro biological activities of evaluated compounds are discussed. 
2. Results and Discussion 
2.1. Chemistry  
We prepared a series of pyrazinamide alkylamino derivatives according to the general procedures  
shown in Scheme 1. 3-Chloro-N-methylpyrazine-2-carboxamide (1) was previously prepared by  
Allen et al. [21], 3-chloro-N-propylpyrazine-2-carboxamide (3) by Zhu et al. [22] and N-methyl-3-
(methylamino)pyrazine-2-carboxamide (9) by Albert et al. [23], but they were not tested  
for any biological activity. The other 27 compounds are novel. Precursors 1–8 were synthesized  
from commercially available 3-chloropyrazine-2-carbonitrile by hydrolysis (Scheme 1, step a) to the 
corresponding acid, conversion to the acyl chloride (step b) and its aminolysis (step c) by the 
corresponding amine. Final products 9–30 were prepared in yields ranging from 41% to 98% by 
aminodehalogenation (step d) in a microwave reactor with a focused field.  
N
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O
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N
N
NH
N
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R1
R2
a b
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d
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75%
46%-64%41%-98%  
Reagents and Conditions: (a) NaOH, H2O, reflux 7–8 h, HCl; (b) SOCl2, DMF, toluene, 95 °C, 1 h; (c) alkylamine, 
TEA, acetone, RT, overnight; (d) alkylamine, pyridine, methanol, MW: 150 °C, 30 min, 100 W. 
Scheme 1. Synthesis of final compounds 1–30. 
All compounds were characterized by 1H-, 13C-NMR and IR spectroscopy, solid compounds by 
melting points and elemental analysis, and liquid compounds by HRMS. 
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2.2. Lipophilicity 
Lipophilicity is one of the most important drug characteristics. It plays a significant role in penetration 
through biological membranes.  
Table 1. Structure of prepared compounds, calculated (log P) and experimentally measured 
(log k) lipophilicity parameters, biological activity against M. tuberculosis H37Rv expressed 
as minimal inhibitory concentration (MIC) and PET-inhibiting activity expressed by  
IC50 value. 
 No. Structure R1 R2 log P log k 
MIC M. tuberculosis 
[µg/mL] 
IC50 [mmol/L] 
G
ro
up
 A
 
1 
 
CH3 - −0.17 −0.747 >100 ND 
2 C2H5 - 0.16 −0.591 >100 ND 
3 C3H7 - 0.65 −0.414 >100 ND 
4 C4H9 - 1.07 −0.209 >100 4.014 
5 C5H11 - 1.49 0.012 >100 1.390 
6 C6H13 - 1.90 0.239 100 1.067 
7 C7H15 - 2.32 0.470 100 0.256 
8 C8H17 - 2.74 0.702 50 0.055 
G
ro
up
 B
 
9 
 
CH3 
CH3 −0.86 −0.279 >100 5.646 
10 C2H5 −0.52 −0.052 >100 ND 
11 C3H7 −0.04 0.166 >100 ND 
12 C4H9 0.38 0.401 100 0.523 
13 C5H11 0.80 0.638 50 0.544 
14 C6H13 1.21 0.876 25 0.125 
15 C7H15 1.63 1.118 25 0.065 
16 C8H17 2.05 1.359 25 0.064 
G
ro
up
 C
 
17 
C2H5 
CH3 −0.52 −0.063 >100 ND 
18 C2H5 −0.19 0.163 >100 ND 
19 C3H7 0.30 0.382 >100 2.047 
20 C4H9 0.72 0.617 >100 1.090 
21 C5H11 1.13 0.855 50 0.301 
22 C6H13 1.55 1.094 50 0.078 
23 C7H15 1.97 1.337 50 0.048 
24 C8H17 2.39 1.579 50 0.056 
G
ro
up
 D
 
25 C3H7 C3H7 0.79 0.600 >100 1.303 
26 C4H9 C4H9 1.62 1.077 50 0.202 
27 C5H11 C5H11 2.46 1.557 >100 0.105 
28 C6H13 C6H13 3.29 2.041 >100 0.272 
29 C7H15 C7H15 4.12 2.503 >100 1.123 
30 C8H17 C8H17 4.96 2.981 >100 0.752 
 DCMU  
INH 
  2.2   0.002 
   −0.64  0.1−0.39  
Experimentally determined values of lipophilicity log k and calculated values of log P of prepared 
compounds are summarized in Table 1 together with corresponding IC50 values related to PET inhibition 
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in spinach chloroplasts and MIC values related to antimycobacterial activity against M. tuberculosis. 
According to their structure, the prepared compounds could be divided into four groups: N-alkyl-3-
chloropyrazine-2-carboxamides (group A; 1–8), 3-(alkylamino)-N-methylpyrazine-2-carboxamides 
(group B; 9–16), 3-(alkylamino)-N-ethylpyrazine-2-carboxamides (group C; 17–24) and N-alkyl-3-
(alkylamino)pyrazine-2-carboxamides (group D; 25–30). At comparable log P values the experimentally 
determined log k values of N-alkyl-3-chloropyrazine-2-carboxamides (group A) were lower than the  
log k values estimated for compounds of groups B, C and D (Figure 1). The dependences of log k vs.  
log P were linear for eight compounds of group A (1) as well as for 22 compounds belonging to groups 
B, C and D (2) and the corresponding correlations provided excellent results of statistical analysis: 
log	݇ ൌ െ0.700ሺേ 0.021ሻ ൅ 0.499ሺേ 0.013ሻ log ܲ (1)
r ൌ 0.998; 	n ൌ 8; 	s ൌ 0.036; 	F ൌ 1400.4 
log	݇ ൌ 0.213ሺേ 0.007ሻ ൅ 0.557ሺേ 0.004ሻ log ܲ (2)
r ൌ 0.9995; 	n ൌ 22; 	s ൌ 0.026; 	F ൌ 22116.7 
 
Figure 1. Plot of experimentally measured log k parameter on calculated log P. 
2.3. Biological Activity 
2.3.1. Antimycobacterial Activity 
Compounds 9–30 were tested for in vitro whole cell activity against M. tuberculosis H37Rv,  
M. kansasii and M. avium. Precursors 1–8 were tested against M. tuberculosis H37Rv only. The most 
active substances against M. tuberculosis were compounds 14–16, i.e., compounds with long alkyl 
chains (hexyl, heptyl and octyl) in the molecule. However, their activity expressed as minimal inhibitory 
concentration (MIC) was only 25 μg/mL (corresponding to 105.8, 99.9 and 94.6 μmol/L, respectively), 
while the activity of standard INH was 0.1–0.39 μg/mL (i.e., 0.7–2.9 μmol/L). 
The antimycobacterial activity of compounds was closely connected with lipophilicity of the 
compounds (Table 1, Figure 2). From the series of N-alkyl-3-chloropyrazine-2-carboxamides (group A) 
the MIC values could be estimated only for three compounds and the results indicate that a strong 
increase in antimycobacterial activity was observed up to log k = 0.702. The dependence of log (1/MIC) 
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on log k for 3-(alkylamino)-N-methylpyrazine-2-carboxamides (group B) was bilinear and strong 
activity increase was observed for log k from 0.401 (12, R2 = C4H9) to 0.876 (14, C6H13), while with 
further lipophilicity increase up to log k = 1.359 the inhibitory activity expressed in molar concentrations 
slightly increased (14–16).  
 
Figure 2. Dependence of antimycobacterial activity of tested compounds against  
M. tuberculosis H37Rv on log k. 
Considerably lower antimycobacterial activity against M. tuberculosis of 3-(alkylamino)-N-
ethylpyrazine-2-carboxamides (group C) in comparison with 3-(alkylamino)-N-methylpyrazine-2-
carboxamides (group B) with comparable lipophilicity indicates that substitution of –CONHCH3 
substituent in position 2 of the pyrazine ring with –CONHC2H5 accompanied with the reduction of alkyl 
chain length by one CH2 group in 3-alkylamino substituent led to significant activity decrease (Table 1). 
For example, compound 14 (group B, R1 = CH3, R2 = C6H13) has a total number of seven carbons in 
aliphatic alkyl chains, lipophilicity of log k = 0.876 and MIC = 25 μg/mL. Compound 21 (group C,  
R1 = C2H5, R2 = C5H11) has an equal number of carbons in aliphatic alkyl chains, similar lipophilicity of 
log k = 0.855, but MIC = 50 μg/mL, i.e., approx. half of the activity of compound 14. Consequently, 
from the aspect of antimycobacterial activity at comparable lipophilicity, longer alkyl chain in  
3-(alkylamino) substituent is favourable. 
Only one compound from group D containing two butyl groups in its molecule (26, R1 = R2 = C4H9) 
was found to be active against M. tuberculosis H37Rv and its activity was comparable with compound 22 
from group C with similar lipophilicity (Figure 2). 
In comparison to derivatives with alkylamino chain in position 5 or 6 previously prepared  
by Servusová et al., i.e., 5-octylaminopyrazine-2-carboxamide (MIC = 6.26 μg/mL) and 6-octylamino- 
pyrazine-2-carboxamide (MIC = 1.56 μg/mL) [11], the compounds presented in this paper were 
generally of lower activity. This decrease in activity can be attributed to the change of the alkylamino 
substituent to position 3 on the pyrazine core. On the other hand, compounds 14–16 showed better  
activity than compounds previously prepared by Jandourek et al., i.e., 3-hexylamino-, 3-heptyamino- 
and 3-octylaminopyrazine-2-carboxamide (MIC = 50 μg/mL) [24]. This indicates that formal  
N-methylation of the carboxamide moiety slightly increases the activity. The activity of tested 
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compounds (group B, C, D) against M. kansasii was in general low (MIC >100 μg/mL) and only for 
compounds 21–24 MIC = 50 μg/mL was estimated. There was no activity against M. avium.  
2.3.2. Antibacterial and Antifungal Activity 
This evaluation was performed in order to obtain results for antifungal and antibacterial activity 
against eight fungal strains and eight bacterial strains of clinical significance. The most effective 
compound against Trichophyton mentagrophytes was 8 (R1 = C8H17) with MIC = 62.5 µmol/L, the 
results of other active compounds are shown in Table 2.  
Table 2. Antifungal activity of studied compounds against Trichophyton mentagrophytes. 
Compound No. MIC [µmol/L] 
6 250 
7 125 
8 62.5 
13 250 
14 250 
15 125 
21 250 
22 125 
23 125 
The dependence of antifungal activity of tested compounds against T. mentagrophytes is shown in 
Figure 3. Although the MIC values were estimated only for two compounds of group A, it is evident 
that antifungal activity of these compounds was significantly higher than the activity of compounds from 
group B and C with comparable lipophilicity.  
 
Figure 3. Dependence of antifungal activity of tested compounds against T. mentagrophytes on log k. 
This indicates that the presence of chloro substituent in position 3 of pyrazine ring significantly 
contributed to antifungal activity. For compounds of group B and D the antifungal activity against  
T. mentagrophytes increased approximately linearly with increasing compound lipophilicity up to  
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log k ≈ 1.334 and with further increase of lipophilicity significant loss of activity was observed. This 
indicates that for antifungal activity of tested compounds the total lipophilicity of substituents in position 
2 and 3 of pyrazine ring is determinant. Compounds 6–8 were active against Aspergillus fumigatus and 
Trichosporon asahii (MIC = 125 µmol/L). Compound 16 showed low activity against Staphylococcus 
aureus (MIC = 250 µmol/L) and compounds 15, 19, 23 and 24 against Staphylococcus epidermidis  
(MIC = 250 µmol/L) in antibacterial assays. 
2.3.3. Antiviral Activity 
All substances were tested for their activity against diverse DNA and RNA viruses. The virus panel 
included pathogens of medical importance such as herpesviruses, HIV and influenza virus. None of the 
prepared compounds displayed any antiviral activity. 
2.3.4. Cytotoxicity Assay 
In vitro cytotoxicity assays on HeLa and Vero cells were performed using standard assays. The results 
were expressed as minimum compound concentration (MCC) that causes a microscopically detectable 
alteration of normal cell morphology. No cytotoxicity was detected up to the highest tested concentration 
of 100 µmol/L, except for 30 (MCC = 100 µmol/L, Vero cells). The highest tested concentration for 28 
in Vero cells assay was 4 µmol/L due to solubility issues.  
2.3.5. Evaluation of Photosynthetic Electron Transport (PET) Inhibiting Activity 
The PET-inhibiting activity was expressed by negative logarithm of IC50 value (compound concentration 
in mol/L causing 50% inhibition of PET). The IC50 values of studied pyrazine-2-carboxamides are shown 
in Table 1. The PET-inhibiting activity of N-alkyl-3-chloropyrazine-2-carboxamides (group A) 
expressed as log (1/IC50) increased linearly (r = 0.977, n = 5) with increasing lipophilicity of the 
compounds from log k = −0.209 (4, R1 = C4H9) to log k = 0.702 (8, R1 = C8H17) (Figure 4, black circles). 
The less lipophilic compounds of group A 1 (R1 = CH3, log k = −0.747), 2 (R1 = C2H5, log k = −0.591) 
and 3 (R1 = C3H7, log k = −0.414) were inactive. Linear dependence of PET-inhibiting activity on the 
lipophilicity expressed as log k (r = 0.9778, n = 6) was observed also for 3-(alkylamino)-N-
methylpyrazine-2-carboxamide (group B, 9–16) (Figure 4, red circles), however N-methyl-3-
(pentylamino)pyrazine-2-carboxamide (13, R2 = C5H11) showed lower activity as expected. On the other 
hand, for N-alkyl-3-(alkylamino)pyrazine-2-carboxamides (group D, 25–30) bilinear dependence of log 
(1/IC50) on log k was estimated with optimum log k = 1.557 (27, R1 = R2 = C5H11) (Figure 4, blue 
triangles). The activity of more lipophilic compounds of this series 28 (R1 = R2 = C6H13, log k = 2.041), 
29 (R1 = R2 = C7H15, log k = 2.503) and 30 (R1 = R2 = C8H17, log k = 2.981) showed strong linear 
decrease with increasing compound lipophilicity. In the series of 3-(alkylamino)-N-ethylpyrazine-2-
carboxamides (group C, 17–24) the PET-inhibiting activity increased linearly with increasing 
lipophilicity of the compounds between log k = 0.382 (19, R2 = C3H7) and log k = 1.337 (23, R2 = C7H15) 
and with further prolongation of the alkyl chain to R2 = C8H17 (24, log k = 1.579) slightly decreased 
(Figure 4, green triangles). The less lipophilic compounds of this series, 3-(methylamino)-N-
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ethylpyrazine-2-carboxamide (17, R2 = CH3, log k = −0.063) and 3-(ethylamino)-N-ethypyrazine-2-
carboxamide (18, R2 = C2H5, log k = 0.163) were not active. 
 
Figure 4. Dependence of PET-inhibiting activity on lipophilicity of studied compounds 
expressed as log k.  
The comparison of PET-inhibiting activity N-alkyl-3-chloropyrazine-2-carboxamides of (group A; 
1–8) with that of N-alkyl-3-(alkylamino)pyrazine-2-carboxamides (group D; 25–30) showed that IC50 
values of N-propyl-3-(propylamino)pyrazine-2-carboxamide (25, log k = 0.600, MIC = 1.303 mmol/L) 
and N-butyl-3-(butylamino)pyrazine-2-carboxamide (26, log k = 1.077, MIC = 0.202 mmol/L) were 23.7 
times and 3.67 times higher than that of N-octyl-3-chloropyrazine-2-carboxamide (8, log k = 0.702,  
MIC = 0.055 mmol/L). Consequently, it is evident that for effective PET inhibition substituent with 
longer alkyl chain in the molecule is more favourable than substituents with two shorter alkyl chains.  
N-pentyl-3-(pentylamino)pyrazine-2-carboxamide (27, MIC = 0.105 mmol/L, log k = 1.557) was the 
most effective compound of group D.  
From comparison of 3-(alkylamino)-N-methylpyrazine-2-carboxamid (group B; 9–16) and  
3-(alkylamino)-N-ethylpyrazine-2-carboxamide (group C; 17–24) at comparable compound lipophilicity 
up to log k ≈ 1.117 compounds of group B showed higher PET-inhibiting activity than compounds of 
group C, however, in the compound lipophilicity range from log k = 1.117 to log k =1.579 the differences 
between activities of the compounds belonging to both groups were low. While the IC50 value of  
3-(propylamino)-N-ethylpyrazine-2-carboxamide (19, IC50 = 2.047 mmol/L, log k = 0.382) was 3.9-fold 
higher than that of 3-(butylamino)-N-methylpyrazine-2-carboxamide (12, IC50 = 0.523 mmol/L,  
log k = 0.401), the IC50 value of 3-(pentylamino)-N-ethylpyrazine-2-carboxamid (21, IC50 = 0.301 mmol/L, 
log k = 0.855) was only 2.4-fold higher than that of 3-(hexylamino)-N-methylpyrazine-2-carboxamide 
(14, IC50 = 0.125, log k = 0.876).  
The loss of a biological activity observed for amphiphilic compounds upon elongation of their 
hydrophobic (hydrocarbon) part is called ‘cut-off’ effect [25,26]. The hydrophobic parts of such 
compounds interact with lipidic parts of biological (including thylakoid) membranes. It could be noted 
that water solubility of compounds with longer alkyl chain is limited and too large values of compound 
partition coefficient did not enable the penetration of such molecules through hydrophilic (aqueous) 
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regions of biological membranes. Thus, the final concentration of long-chain compounds in the 
membrane will be lower than that of compounds with shorter alkyl chain, and this phenomenon is 
connected with loss of biological activity. According to the free volume theory the extent of membrane 
disturbance due to incorporation of compound containing alkyl chain depends on the size of free volume 
created under its alkyl chain which can be then filled up with chains of neighbouring lipids as well as on 
the partition coefficient of the compounds [25–28]. Therefore the most effective disturbance of the 
membrane and thus the highest inhibitory activity is shown by compounds with middle alkyl chain length 
ensuring not only sufficiently high free volume under alkyl chain but also high concentration of the 
compound in the membrane due to suitable value of compound partition coefficient.  
Moreover compounds with CONH group(s) in their molecules can interact with amino acid 
constituents in proteins resulting in the loss of their function. It should be stressed that the CONH group 
is characteristic of many herbicides [12,29] and it could also to a certain extent contribute to  
their inhibitory effects. For example, the determined IC50 value related to PET inhibition for  
N,N'-bis(2-dimethylaminoethyl)ethanediamide (which does not contain a long alkyl chain) was found to 
be 4.0 mmol/L, while the corresponding IC50 value estimated for 3,8-diaza-4,7-dioxodecane-1,10-
diylbis(nonyldimethyl)ammonium bromide was 1.74 mmol/L [30]. This indicates that CONH groups in 
spacer of this surfactant molecule participated on the resulting inhibitory effects. Because studied 
pyrazine-2-carboxamide derivatives do not contain in their structure longer alkyl chain than octyl, by 
analogy with above mentioned surfactants it could be assumed that CONH group also participates in 
PET inhibition, as it was shown previously by fluorescence experiments [24,31].  
Strong dependence of the PET-inhibiting activity on the alkyl chain length of the alkoxy substituent 
was estimated previously for esters of 2-, 3- and 4-alkoxy substituted phenylcarbamic acids  
(alkyl = methyl – decyl). For these compounds the dependence of log (1/IC50) vs. alkyl chain length 
showed a typical quasi-parabolic course with maximum effect at 6–8 carbon atoms in the alkyl chain of 
piperidinoethylesters [13], 7–9 carbon atoms in the alkyl chain of dimethylaminoethylesters [32] and  
8–9 carbon atoms in the alkyl chain of piperidinopropyl esters of alkoxyphenylcarbamic acids [33,34]. 
Because the tested pyrazine-2-carboxamides inhibited Hill reaction, similarly to previously studied 
pyrazine derivatives [14,20], they can be considered as photosystem 2 (PS2) inhibitors. The PS2 
inhibitors can act on the donor and/or the acceptor side of PS2. Interaction of N-phenylpyrazine-2-
carboxamides with the D• intermediate which is situated at 161st position in D2 protein occurring on the 
donor side of PS2 was confirmed previously by EPR spectroscopy. Due to this interaction the 
photosynthetic electron transport from the oxygen evolving complex to the reaction centre of PS2 was 
impaired and consequently, the electron transport between PS2 and PS1 was inhibited.  
2,5-Diphenylcarbazide (DPC) is an artificial electron donor acting in Z/D intermediate on the donor 
side of PS2 [35]. After addition of DPC to chloroplasts which activity had been inhibited by studied 
compounds to 75%, the PET was gradually restored with increasing DPC concentration. However, for 
complete restoration of PET, approximately five-fold higher DPC concentration was necessary compared 
to the applied concentration of inhibitor. This indicates that the studied compounds could damage PET 
also in the section between P680 and secondary quinone acceptor QB on the acceptor side of PS2. The 
binding of compounds with herbicidal activity, e.g., atrazine or metribuzine, was found to be altered by 
DPC presumably because of overlapping binding domain in the QB pocket, however DPC on the QB site 
affected plastoquinone reduction only at relatively high concentrations [36,37]. For PS2 hebicides such 
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are DCMU or atrazin also a second binding site situated on the donor side of PS2 near Z/D intermediates 
and the high-affinity Mn-binding sites was described by several researchers [38–40]. Based on these 
finding as well as on above mentioned results related to interaction of N-phenylpyrazine-2-carboxamides 
with the D• intermediate on the donor side of PS2, we assume similar site of action also for the studied 
pyrazinamide alkylamino derivatives.  
The three amino acids with aromatic ring side chains—phenylalanine, tyrosine and especially 
tryptophan—are sensitive to the local electrostatic environment in proteins and they will undergo 
fluorescence wavelength and/or intensity changes upon whatever functional process a protein  
performs [41]. Interaction of substituted pyrazine-2-carboxamides with residues of aromatic amino acids 
(AAA), mainly tryptophan and tyrosine occurring in photosynthetic proteins situated predominantly in PS2, 
was documented by the quenching of AAA fluorescence at 334 nm (Figure 5A). Figure 5A presents 
fluorescence emission spectra of AAA of untreated spinach chloroplasts and of chloroplasts treated with 
increasing concentrations of compound 16 (R1 = CH3, R2 = C8H17). As shown in this Figure, the 
quenching of the fluorescence of aromatic amino acids at 334 nm increased with increasing 
concentration of pyrazine derivative In Figure 5B linear dependences of fluorescence intensity of AAA 
(expressed as % of control) on concentration of compounds 27 (R1 = R2 = C6H13) and 16 are shown. The 
extent of fluorescence decline with increasing compound concentration expressed by slope of  
this dependence correlated with IC50 values determined using Hill reaction (16: IC50 = 64.0 μmol/L, 
slope = −0.668, r = 0.989 and 27: IC50= 105.0 μmol/L, slope = −0.211, r = 0.992). These results indicate 
that interaction of studied pyrazine derivatives with aromatic amino acids residues occurring in 
photosynthetic proteins contributed to PET inhibition.  
 
Figure 5. (A) Fluorescence emission spectra of aromatic amino acids in suspension of 
spinach chloroplasts without and with compound 16 (c = 0, 10, 25, 49, 74 and 123 μmol/L; 
the curves from top to bottom); (B) Dependence of intensity of aromatic amino acids 
fluorescence emission band (expressed as % of control) at 340 nm in suspension of spinach 
chloroplasts on the concentration of studied compounds: 27 and 16. Excitation wave  
length λ = 275 nm; chlorophyll concentration 10 mg/L. 
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The quenching of the fluorescence of aromatic amino acids in the presence of 5-bromo- and  
3,5-dibromo-2-hydroxy-N-phenylbenzamides [42] and ring-substituted 2-hydroxynaphthalene-1-
carboxanilides [31] was observed previously. 
3. Experimental Section 
3.1. General Information 
All chemicals were of reagent or higher grade of purity and were purchased from Sigma-Aldrich 
(Steinheim, Germany), unless stated otherwise. The progress of the reaction was checked by Thin Layer 
Chromatography (TLC) (Alugram® Sil G/UV254, Machery-Nagel, Postfach, Germany) with UV 
detection using wavelength 254 nm. Microwave assisted reactions were performed in a CEM Discover 
microwave reactor with a focused field (CEM Corporation, Matthews, NC, USA) connected to  
an Explorer 24 autosampler (CEM Corporation) and this equipment was running under CEM’s 
SynergyTM software for setting and monitoring the conditions of reactions. The temperature of the 
reaction mixture was monitored by internal infrared sensor. All obtained products were purified by 
preparative flash chromatograph CombiFlash® Rf (Teledyne Isco Inc., Lincoln, NE, USA). The type of 
elution was gradient, using the mixture of hexane (LachNer, Neratovice, Czech Republic) and ethyl 
acetate (Penta, Prague, Czech Republic) as mobile phase. Silica gel (0.040–0.063 nm, Merck, Darmstadt, 
Germany) was used as the stationary phase. NMR spectra were recorded on Varian Mercury-VxBB 300 
with frequencies 299.95 MHz for 1H and 75.43 MHz for 13C or Varian VNMR S500 (499.87 MHz for 
1H and 125.71 MHz for 13C) spectrometers (Varian Corporation, Palo Alto, CA, USA). Chemical shifts 
were reported in ppm (δ) and were referred indirectly to tetramethylsilane via signal of solvent (2.49 for 
1H and 39.7 for 13C in DMSO-d6). Infrared spectra were recorded with spectrometer FT-IR Nicolet 6700 
(Thermo Scientific, Waltham, MA, USA) using attenuated total reflectance (ATR) methodology. 
Elemental analyses were measured with EA 1110 CHNS Analyzer (Fisons Instruments S. p. A., Carlo 
Erba, Milano, Italy). UHPLC system Acquity UPLC I-class (Waters, Millford, MA, USA) coupled to 
high resolution mass spectrometer (HRMS) Synapt G2Si (Waters, Manchester, UK) based on Q-TOF 
were used for HRMS spectra measurement. Chromatography was performed using Acquity UPLC BEH 
C18 (2.1 × 100 mm, 1.7 um) column using gradient elution with acetonitrile and 0.1% formic acid at 
flow-rate 0.4 mL/min. Electrospray ionization was operated in positive mode. The ESI spectra were 
recorded in the range 50–1200 m/z using leucine-enkefaline as a lock mass reference and sodium formate 
for mass calibration. Melting points were assessed by SMP3 Stuart Scientific (Bibby Sterling Ltd., 
Staffordshire, UK) in open capillary and are uncorrected. Lipophilicity parameter log P was calculated 
by software CS ChemBioDraw Ultra 13.0 (CambridgeSoft, Cambridge, MA, USA). 
3.2. Synthesis 
The starting compound 3-chloropyrazine-2-carbonitrile (Fluorochem Ltd., Hadfield, Derbyshire, 
UK) was hydrolysed to 3-chloropyrazine-2-carboxylic acid (3-Cl-POA) in basic aqueous solution. 
3-Chloropyrazine-2-carbonitrile (35.8 mmol) was added into 10% solution of sodium hydroxide  
(125 mmol, 3.5 equiv). The reaction mixture was stirred and heated under reflux in an oil bath for 
approximately 7–8 h. The progress of reaction was monitored by TLC in system butanol/acetic acid/water 
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(4:1:5). The reaction mixture was acidified by 10% solution of hydrochloric acid to pH 3. Newly-emerged 
crystals were suctioned. 
3-Cl-POA (1.0 g, 6.3 mmol) was dispersed in dry toluene (approx. 50 mL) with thionyl chloride  
(1.4 mL, 18.9 mmol, 3 equiv.) and a catalytic amount (1–2 drops) of N,N-dimethylformamide (DMF). 
The reaction mixture in round bottomed flask was stirred and heated in an oil bath under a condenser at 
95 °C for approximately 1 h. Solvents were evaporated in vacuo and the residue was azeotroped with 
dry toluene (3 × 20 mL) to remove the unreacted SOCl2 to yield crude acyl chloride [43] as brown solid, 
which was used without further purification.  
The whole amount of 3-chloropyrazine-2-carbonyl chloride prepared in the previous step was 
dissolved in dry acetone. An appropriate alkylamine (18.9 mmol, 3 equiv.) along with triethylamine 
(0.64 g, 6.3 mmol, 1 equiv.) were added to the reaction mixture and stirred at laboratory temperature 
overnight [43]. The progress of reaction was checked by TLC in system hexane/ethyl acetate  
(1:1 or 2:1). The reaction mixture was adsorbed to silica by removing the solvents in vacuo and the 
product was purified by flash chromatography using gradient elution with ethyl acetate in hexane. 
Precursors 1–8 were recrystallized from EtOH/H2O if needed.  
Aminodehalogenation of N-alkyl-3-chloropyrazine-2-carboxamides 1–8 was completed using a 
microwave reactor with focused field. Precursors 1–8 (1 mmol) were dissolved in methanol (3 mL), 
appropriate alkylamine (3 mmol, 3 equiv.) and pyridine (80 mg, 1 mmol, 1 equiv.) as a base were added. 
Conditions used for synthesis were 150 °C, 1 h, 100 W. The progress of reaction was monitored by TLC 
in system hexane/ethyl acetate (1:1). The reaction mixture was adsorbed to silica by removing the 
solvents in vacuo and the product was purified by flash chromatography using gradient elution with 
ethyl acetate in hexane. Methylamine was used as 33% (m/m) aqueous solution. 
3.3. Analytical Data 
3-Chloro-N-methylpyrazine-2-carboxamide (1) [21]. Pale yellow solid. Yield 63.8%; m. p.  
104.8–106.7 °C; IR (ATR-Ge, cm−1): 3303 (N-H, CONH), 1662 (C=O, CONH); 1H-NMR (300 MHz, 
CDCl3) δ 8.51 (d, J = 2.3 Hz, 1H), 8.46 (d, J = 2.3 Hz, 1H), 7.57 (s, 1H), 3.02 (d, J = 5.1 Hz, 3H);  
13C-NMR (75 MHz, CDCl3) δ 162.62, 148.14, 145.56, 143.28, 140.52, 26.39; Elemental analysis: calc. 
for C6H6ClN3O (MW 171.58): 42.00% C, 3.52% H, 24.49% N; found 42.17% C, 3.87% H, 24.37% N. 
3-Chloro-N-ethylpyrazine-2-carboxamide (2). Pale yellow solid. Yield 50.8%; m. p. 110.5–112.2 °C; 
IR (ATR-Ge, cm−1): 3285 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.51 (d, 
J = 2.2 Hz, 1H), 8.46 (d, J = 2.3 Hz, 1H), 7.54 (s, 1H), 3.55–3.45 (m, 2H), 1.26 (t, J = 7.3 Hz, 3H);  
13C-NMR (75 MHz, CDCl3δ 161.86, 148.19, 145.51, 143.36, 140.49, 34.63, 14.62; Elemental analysis: 
calc. for C7H8ClN3O (MW 185.61): 45.30% C, 4.34% H, 22.64% N; found 45.59% C, 4.71% H, 23.12% N. 
3-Chloro-N-propylpyrazine-2-carboxamide (3) [22]. Pale brown solid. Yield 45.0%; m. p. 93.3–95.0 °C; 
IR (ATR-Ge, cm−1): 3281 (N-H, CONH), 1656 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.76 
(t, 1H), 8.68 (d, J = 2.5 Hz, 1H), 8.62 (d, J = 2.5 Hz, 1H), 3.27–3.18 (m, 2H), 1.59–1.46 (m, 2H), 0.90 
(t, J = 7.4 Hz, 3H); 13C-NMR (75 MHz, DMSO-d6) δ 163.74, 148.67, 145.29, 145.12, 142.62, 40.76, 
22.34, 11.54; Elemental analysis: calc. for C8H10ClN3O (MW 199.64): 48.13% C, 5.05% H, 21.05% N; 
found 48.25% C, 5.54% H, 21.36% N.  
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N-Butyl-3-chloropyrazine-2-carboxamide (4). Pale brown solid. Yield 45.8%; m. p. 78.9–79.4 °C; IR 
(ATR-Ge, cm−1): 3276 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.75 (s, 
1H), 8.68 (d, J = 2.5 Hz, 1H), 8.62 (d, J = 2.5 Hz, 1H), 3.30–3.22 (m, 2H), 1.55–1.44 (m, 2H),  
1.41–1.28 (m, 2H), 0.89 (t, J = 7.2 Hz, 3H); 13C-NMR (75 MHz, DMSO-d6) δ 163.69, 148.67, 145.28, 
145.11, 142.62, 38.64, 31.08, 19.68, 13.81; Elemental analysis: calc. for C9H12ClN3O (MW 213.67): 
50.59% C, 5.66% H, 19.67% N; found 50.32% C, 6.12% H, 19.74% N. 
3-Chloro-N-pentylpyrazine-2-carboxamide (5). Pale yellow solid. Yield 43.9%; m. p. 80.6–82.2 °C; IR 
(ATR-Ge, cm−1): 3275 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6)  
δ 8.75 (s, 1H), 8.68 (d, J = 2.5 Hz, 1H), 8.65–8.59 (m, 1H), 3.29–3.20 (m, 2H), 1.56–1.43 (m, 2H),  
1.39–1.17 (m, 4H), 0.88 (t, 3H); 13C-NMR (75 MHz, DMSO-d6) δ 163.68, 148.67, 145.29, 145.11, 
142.64, 38.93, 28.70, 28.66, 21.98, 14.13; Elemental analysis: calc. for C10H14ClN3O (MW 227.69): 
52.75% C, 6.20% H, 18.46% N; found 52.31% C, 6.64% H, 18.02% N. 
3-Chloro-N-hexylpyrazine-2-carboxamide (6). Pale brown solid. Yield 46.9%; m. p. 77.3–78.1 °C; IR 
(ATR-Ge, cm−1): 3277 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.74 (t, 
1H), 8.68 (d, J = 2.5 Hz, 1H), 8.61 (d, J = 2.5 Hz, 1H), 3.29–3.20 (m, 2H), 1.56–1.44 (m, 2H),  
1.37–1.20 (m, 6H), 0.87 (t, 3H); 13C-NMR (75 MHz, DMSO-d6) δ 163.68, 148.68, 145.28, 145.12, 
142.63, 38.96, 31.10, 28.94, 26.16, 22.25, 14.09; Elemental analysis: calc. for C11H16ClN3O (MW 
241.72): 54.66% C, 6.67% H, 17.38% N; found 54.30% C, 6.89% H, 16.96% N. 
3-Chloro-N-heptylpyrazine-2-carboxamide (7). Pale brown solid. Yield 40.3%; m. p. 82.1–83.0 °C; IR 
(ATR-Ge, cm−1): 3275 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.51 (d,  
J = 2.3 Hz, 1H), 8.46 (d, J = 2.3 Hz, 1H), 7.54 (s, 1H), 3.49–3.40 (m, 2H), 1.68–1.57 (m, 2H),  
1.38–1.23 (m, 8H), 0.86 (t, 3H); 13C-NMR (75 MHz, CDCl3) δ 161.93, 148.23, 145.48, 143.44, 140.49, 
39.78, 31.68, 29.41, 28.90, 26.89, 22.55, 14.03; Elemental analysis: calc. for C12H18ClN3O (MW 
255.75): 56.36% C, 7.09% H, 16.43% N; found 56.41% C, 7.37% H, 16.07% N. 
3-Chloro-N-octylpyrazine-2-carboxamide (8). Pale yellow solid. Yield 47.1%; m. p. 85.4–86.6 °C; IR 
(ATR-Ge, cm−1): 3277 (N-H, CONH), 1660 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.74 (t, 
1H), 8.68 (d, J = 2.4 Hz, 1H), 8.61 (d, J = 2.6 Hz, 1H), 3.29–3.20 (m, 2H), 1.55–1.44 (m, 2H),  
1.35–1.20 (m, 10H), 0.84 (t, 3H); 13C-NMR (75 MHz, DMSO-d6) δ 163.67, 148.67, 145.28, 145.11, 
142.63, 38.95, 31.42, 28.98, 28.85, 28.82, 26.49, 22.28, 14.15; Elemental analysis: calc. for C13H20ClN3O 
(MW 269.77): 57.88% C, 7.47% H, 15.58% N; found 57.97% C, 7.25% H, 15.67% N. 
N-Methyl-3-(methylamino)pyrazine-2-carboxamide (9) [23]. Pale yellow solid. Yield 66.9%; m. p.  
75.1–76.1 °C (in lit. 73 °C [23]); IR (ATR-Ge, cm−1): 3363, 3275 (N-H, CONH, NH), 1660 (C=O, 
CONH; 1H-NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 8.16 (d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.61 (d,  
J = 2.5 Hz, 1H), 3.01 (d, J = 4.9 Hz, 3H), 2.95 (d, J = 5.2 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 167.05, 
155.20, 146.29, 128.90, 126.88, 27.23, 25.77; Elemental analysis: calc. for C7H10N4O (MW 166.18): 
50.59% C, 6.07% H, 33.71% N; found 50.23% C, 6.11% H, 33.85% N. 
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3-(Ethylamino)-N-methylpyrazine-2-carboxamide (10). Yellow solid. Yield 83.1%; m. p. 60.9–62.8 °C; 
IR (ATR-Ge, cm−1): 3376, 3306 (N-H, CONH, NH), 1641 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) 
δ 8.63 (s, 1H), 8.14 (d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.60 (d, J = 2.3 Hz, 1H), 3.51–3.45 (m, 2H), 2.95 
(d, J = 5.1 Hz, 3H), 1.26 (t, J = 7.2 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.12, 154.49, 146.21, 
128.89, 126.52, 35.24, 25.72, 14.59; Elemental analysis: calc. for C8H12N4O (MW 180.21): 53.32% C, 
6.71% H, 31.09% N; found 52.89% C, 6.80% H, 30.73% N. 
N-Methyl-3-(propylamino)pyrazine-2-carboxamide (11). Yellow solid. Yield 84.4%; m. p. 32.1–33.9 °C; 
IR (ATR-Ge, cm−1): 3367, 3314 (N-H, CONH, NH), 1645 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) 
δ 8.74 (s, 1H), 8.13 (d, J = 2.4 Hz, 1H), 7.89 (s, 1H), 7.60 (d, J = 2.4 Hz, 1H), 3.45–3.40 (m, 2H), 2.95 
(d, J = 5.2 Hz, 3H), 1.70–1.62 (m, 2H), 0.99 (t, J = 7.4 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.05, 
154.43, 145.76, 128.81, 126.78, 42.38, 25.76, 22.47, 11.58; Elemental analysis: calc. for C9H14N4O 
(MW 194.24): 55.65% C, 7.27% H, 28.85% N; found 55.66% C, 7.30% H, 28.48% N. 
3-(Butylamino)-N-methylpyrazine-2-carboxamide (12). Brown liquid. Yield 40.9%; IR (ATR-Ge, cm-1): 
3367, 3314 (N-H, CONH, NH), 1654 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) δ 8.69 (s, 1H), 8.13 
(d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.42 (m, 2H), 2.95 (d, J = 5.1 Hz, 3H), 
1.66–1.58 (m, 2H), 1.47–1.39 (m, 2H), 0.93 (t, J = 7.4 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.10, 
154.51, 145.95, 128.80, 126.67, 40.27, 31.33, 25.75, 20.23, 13.79; HRMS [M+H]+: calc. for C10H16N4O 
(MW 208.27): 209.1397; found 209.1403. 
N-Methyl-3-(pentylamino)pyrazine-2-carboxamide (13). Yellow liquid. Yield 88.9%; IR (ATR-Ge, cm−1): 
3395, 3320 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) δ 8.73 (s, 1H), 8.12 
(d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.44 (q, J = 7.1, 5.5 Hz, 2H), 2.94 (d,  
J = 5.1 Hz, 3H), 1.67–1.60 (m, 2H), 1.40–1.31 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H); 13C-NMR  
(126 MHz, CDCl3) δ 167.02, 154.33, 145.68, 128.76, 126.80, 40.63, 29.20, 28.92, 25.75, 22.38, 13.92; 
HRMS [M+H]+: calc. for C11H18N4O (MW 222.29): 223.1553; found 223.1562. 
3-(Hexylamino)-N-methylpyrazine-2-carboxamide (14). Yellow liquid. Yield 88.5%; IR (ATR-Ge, 
cm−1): 3407, 3310 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) δ 8.71 (s, 
1H), 8.13 (d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.42 (m, 2H), 2.95 (d,  
J = 5.1 Hz, 3H), 1.67–1.60 (m, 2H), 1.43–1.36 (m, 2H), 1.33–1.26 (m, 4H), 0.90–0.84 (m, 3H);  
13C-NMR (126 MHz, CDCl3) δ 167.06, 154.42, 145.83, 128.78, 126.74, 40.65, 31.53, 29.22, 26.76, 
25.76, 22.52, 13.99; HRMS [M+H]+: calc. for C12H20N4O (MW 236.32): 237.1710; found 237.1720. 
3-(Heptylamino)-N-methylpyrazine-2-carboxamide (15). Yellow liquid. Yield 81.3%; IR (ATR-Ge, cm−1): 
3406, 3310 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.13 
(d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.39 (m, 2H), 2.95 (d, J = 5.1 Hz, 3H), 
1.69–1.58 (m, 2H), 1.43–1.23 (m, 8H), 0.91–0.82 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 167.19, 
154.71, 146.32, 128.84, 126.48, 40.53, 31.73, 29.31, 29.04, 27.08, 25.77, 22.60, 14.05; HRMS [M+H]+: 
calc. for C13H22N4O (MW 250.35): 251.1866; found 251.1875. 
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N-Methyl-3-(octylamino)pyrazine-2-carboxamide (16). Yellow liquid. Yield 90.3%; IR (ATR-Ge, cm−1): 
3408, 3319 (N-H, CONH, NH), 1656 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.13 
(d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.58 (d, J = 2.4 Hz, 1H), 3.47–3.39 (m, 2H), 2.95 (d, J = 5.2 Hz, 3H), 
1.68–1.57 (m, 2H), 1.44–1.20 (m, 10H), 0.90–0.82 (m, 3H); 13C-NMR (75 MHz, CDCl3) δ 167.18, 
154.70, 146.33, 128.82, 126.45, 40.52, 31.79, 29.32, 29.29, 29.17, 27.11, 25.75, 22.61, 14.05; HRMS 
[M+H]+: calc. for C14H24N4O (MW 264.37): 265.2023; found 265.2030. 
N-Ethyl-3-(methylamino)pyrazine-2-carboxamide (17). Yellow liquid. Yield 73.8%; IR (ATR-Ge, cm−1): 
3408, 3326 (N-H, CONH, NH), 1651 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.61 (s, 1H), 8.16 
(d, J = 2.4 Hz, 1H), 7.87 (s, 1H), 7.61 (d, J = 2.5 Hz, 1H), 3.47–3.36 (m, 2H), 3.01 (d, J = 4.9 Hz, 3H), 
1.23 (t, J = 7.3 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.29, 155.22, 146.11, 128.84, 126.96, 33.97, 
27.25, 14.75; HRMS [M+H]+: calc. for C8H12N4O (MW 180.21): 181.1084; found 181.1092. 
N-Ethyl-3-(ethylamino)pyrazine-2-carboxamide (18). Yellow liquid. Yield 89.0%; IR (ATR-Ge, cm−1): 
3395, 3321 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.79 (t, J = 6.1 Hz, 
1H), 8.70 (t, J = 5.6 Hz, 1H), 8.22 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 2.4 Hz, 1H), 3.45–3.35 (m, 2H), 
3.33–3.20 (m, 2H), 1.19–1.05 (m, 6H); 13C-NMR (75 MHz, DMSO-d6) δ 165.99, 154.21, 146.37, 
129.44, 126.65, 34.80, 33.61, 14.92, 14.73; HRMS [M+H]+: calc. for C9H14N4O (MW 194.24): 
195.1240; found 195.1246. 
N-Ethyl-3-(propylamino)pyrazine-2-carboxamide (19). Brown liquid. Yield 95.3%; IR (ATR-Ge, cm−1): 
3395, 3309 (N-H, CONH, NH), 1652 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.72 (s, 1H), 8.13 
(d, J = 2.3 Hz, 1H), 7.88 (s, 1H), 7.60 (d, J = 2.3 Hz, 1H), 3.48–3.37 (m, 4H), 1.73–1.59 (m, 2H), 1.23 
(t, J = 7.3 Hz, 3H), 0.99 (t, J = 7.4 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.42, 154.77, 146.19, 
128.80, 126.53, 42.27, 33.96, 22.50, 14.78, 11.63; HRMS [M+H]+: calc. for C10H16N4O (MW 208.27): 
209.1397; found 209.1402. 
3-(Butylamino)-N-ethylpyrazine-2-carboxamide (20). Yellow liquid. Yield 97.5%; IR (ATR-Ge, cm−1): 
3396, 3314 (N-H, CONH, NH), 1651 (C=O, CONH); 1H-NMR (500 MHz, CDCl3) δ 8.77 (s, 1H), 8.12 
(d, J = 2.5 Hz, 1H), 7.88 (s, 1H), 7.60 (d, J = 2.5 Hz, 1H), 3.48–3.39 (m, 4H), 1.66–1.59 (m, 2H),  
1.47–1.38 (m, 2H), 1.23 (t, J = 7.3 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 
166.25, 154.36, 145.52, 128.70, 126.90, 40.37, 33.97, 31.30, 20.22, 14.74, 13.78; HRMS [M+H]+: calc. 
for C11H18N4O (MW 222.29): 223.1553; found 223.1563. 
N-Ethyl-3-(pentylamino)pyrazine-2-carboxamide (21). Yellow liquid. Yield 93.7%; IR (ATR-Ge, cm−1): 
3395, 3309 (N-H, CONH, NH), 1652 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.68 (s, 1H), 8.13 
(d, J = 2.4 Hz, 1H), 7.89 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.36 (m, 4H), 1.69–1.58 (m, 2H), 1.41–1.31 
(m, 4H), 1.23 (t, J = 7.2 Hz, 3H), 0.90 (t, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.42, 154.77, 146.27, 
128.76, 126.46, 40.48, 33.94, 29.24, 28.97, 22.41, 14.76, 13.94 HRMS [M+H]+: calc. for C12H20N4O 
(MW 236.32): 237.1710; found 237.1720. 
N-Ethyl-3-(hexylamino)pyrazine-2-carboxamide (22). Yellow liquid. Yield 71.2%; IR (ATR-Ge, cm−1): 
3396, 3315 (N-H, CONH, NH), 1654 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.13 
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(d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.37 (m, 4H), 1.68–1.57 (m, 2H),  
1.45–1.27 (m, 6H), 1.23 (t, J = 7.3 Hz, 3H), 0.88 (t, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.44, 154.79, 
146.28, 128.77, 126.48, 40.53, 33.95, 31.55, 29.26, 26.80, 22.54, 14.78, 14.02 HRMS [M+H]+: calc. for 
C13H22N4O (MW 250.35): 251.1866; found 251.1876. 
N-Ethyl-3-(heptylamino)pyrazine-2-carboxamide (23). Yellow liquid. Yield 82.4%; IR (ATR-Ge, 
cm−1): 3396, 3310 (N-H, CONH, NH), 1653 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.67 (s, 
1H), 8.13 (d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.3 Hz, 1H), 3.47–3.37 (m, 4H), 1.69–1.57 (m, 
2H), 1.42–1.20 (m, 11H), 0.85 (t, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.44, 154.79, 146.28, 128.77, 
126.48, 40.52, 33.95, 31.73, 29.30, 29.03, 27.08, 22.59, 14.78, 14.04; HRMS [M+H]+: calc. for 
C14H24N4O (MW 264.37): 265.2023; found 265.2032. 
N-Methyl-3-(octylamino)pyrazine-2-carboxamide (24). Yellow liquid. Yield 70.4%; IR (ATR-Ge, cm−1): 
3395, 3309 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.13 
(d, J = 2.4 Hz, 1H), 7.88 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.47–3.37 (m, 4H), 1.68–1.58 (m, 2H), 1.42–1.20 
(m, 13H), 0.85 (t, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.44, 154.79, 146.29, 128.77, 126.48, 40.53, 
33.96, 31.80, 29.32, 29.29, 29.17, 27.12, 22.61, 14.78, 14.05; HRMS [M+H]+: calc. for C15H26N4O (MW 
278.40): 279.2179; found 279.2190. 
N-Propyl-3-(propylamino)pyrazine-2-carboxamide (25). Yellow liquid. Yield 97.6%; IR (ATR-Ge, cm−1): 
3395, 3315 (N-H, CONH, NH), 1657 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.71 (s, 1H), 8.13 
(d, J = 2.3 Hz, 1H), 7.95 (s, 1H), 7.60 (d, J = 2.4 Hz, 1H), 3.45–3.30 (m, 4H), 1.76–1.55 (m, 4H), 1.03–0.94 
(m, 6H); 13C-NMR (75 MHz, CDCl3) δ 166.56, 154.83, 146.27, 128.82, 126.50, 42.26, 40.81, 22.85, 
22.50, 11.64, 11.45; HRMS [M+H]+: calc. for C11H18N4O (MW 222.29): 223.1553; found 223.1563. 
N-Butyl-3-(butylamino)pyrazine-2-carboxamide (26). Yellow liquid. Yield 92.9%; IR (ATR-Ge, cm−1): 
3398, 3312 (N-H, CONH, NH), 1657 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.68 (s, 1H), 8.13 
(d, J = 2.4 Hz, 1H), 7.92 (s, 1H), 7.59 (d, J = 2.4 Hz, 1H), 3.48–3.34 (m, 4H), 1.68–1.52 (m, 4H),  
1.49–1.33 (m, 4H), 0.97–0.89 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 166.51, 154.80, 146.27, 128.78, 
126.51, 40.20, 38.83, 31.63, 31.36, 20.27, 20.13, 13.83, 13.73; HRMS [M+H]+: calc. for C13H22N4O 
(MW 250.35): 251.1866; found 251.1874. 
N-Pentyl-3-(pentylamino)pyrazine-2-carboxamide (27). Yellow liquid. Yield 93.8%; IR (ATR-Ge, cm−1): 
3398, 3312 (N-H, CONH, NH), 1657 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.68 (s, 1H), 8.13 
(d, J = 2.4 Hz, 1H), 7.92 (s, 1H), 7.60 (d, J = 2.3 Hz, 1H), 3.47–3.33 (m, 4H), 1.69–1.54 (m, 4H), 1.42–1.29 
(m, 8H), 0.93–0.86 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 166.49, 154.79, 146.26, 128.78, 126.52, 
40.52, 39.12, 29.27, 29.11, 28.99, 22.43, 22.35, 13.96; HRMS [M+H]+: calc. for C15H26N4O (MW 
278.40): 279.2179; found 279.2190. 
N-Hexyl-3-(hexylamino)pyrazine-2-carboxamide (28). Yellow liquid. Yield 89.0%; IR (ATR-Ge, cm−1): 
3394, 3313 (N-H, CONH, NH), 1655 (C=O, CONH); 1H-NMR (300 MHz, DMSO-d6) δ 8.80–8.71 (m, 
2H), 8.20 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 2.5 Hz, 1H), 3.36 (q, J = 6.5 Hz, 2H), 3.21 (q, J = 6.8 Hz, 
2H), 1.57–1.42 (m, 4H), 1.34–1.18 (m, 12H), 0.86–0.79 (m, 6H); 13C-NMR (75 MHz, DMSO-d6) δ 
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166.12, 154.37, 146.33, 129.35, 126.60, 39.94, 38.72, 31.19, 29.22, 28.93, 26.41, 26.29, 22.24, 14.05; 
HRMS [M+H]+: calc. for C17H30N4O (MW 306.45): 307.2492; found 307.2498. 
N-Heptyl-3-(heptylamino)pyrazine-2-carboxamide (29). Yellow liquid. Yield 67.7%; IR (ATR-Ge, cm−1): 
3398, 3307 (N-H, CONH, NH), 1658 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.70 (t, J = 5.0 Hz, 
1H), 8.14 (d, J = 2.4 Hz, 1H), 7.92 (t, J = 5.7 Hz, 1H), 7.60 (d, J = 2.5 Hz, 1H), 3.48–3.33 (m, 4H), 
1.69–1.54 (m, 4H), 1.43–1.21 (m, 16H), 0.91–0.83 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 166.46, 
154.74, 146.16, 128.77, 126.59, 40.58, 39.17, 31.74, 31.71, 29.60, 29.30, 29.04, 28.95, 27.10, 26.95, 
22.60, 22.56, 14.06, 14.03; HRMS [M+H]+: calc. for C19H34N4O (MW 334.51): 335.2805; found 335.2809. 
N-Octyl-3-(octylamino)pyrazine-2-carboxamide (30). Yellow liquid. Yield 94.1%; IR (ATR-Ge, cm−1): 
3394, 3310 (N-H, CONH, NH), 1658 (C=O, CONH); 1H-NMR (300 MHz, CDCl3) δ 8.69 (t,  
J = 5.3 Hz, 1H), 8.14 (d, J = 2.5 Hz, 1H), 7.92 (t, J = 5.7 Hz, 1H), 7.60 (d, J = 2.5 Hz, 1H), 3.48–3.33 
(m, 4H), 1.70–1.54 (m, 4H), 1.41–1.23 (m, 20H), 0.90–0.83 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ 
166.50, 154.80, 146.29, 128.78, 126.54, 40.55, 39.16, 31.80, 31.76, 29.59, 29.33, 29.30, 29.24,  
29.16, 27.13, 26.98, 22.60, 14.07; HRMS [M+H]+: calc. for C21H38N4O (MW 362.56): 363.3118;  
found 363.3123. 
3.4. Determination of Lipophilicity by HPLC (Log k) 
Instrumentation: Agilent Technologies 1200 SL liquid chromatograph with Diode-array Detector SL 
G1315C (Agilent Technologies Inc., Colorado Springs, CO, USA); pre-column ZORBAX XDB-C18  
5 μm, 4 × 4 mm, Part No. 7995118-504 (Agilent Technologies Inc.) and column ZORBAX Eclipse 
XDB-C18 5 μm, 4.6 × 250 mm, Part No. 7995118-585 (Agilent Technologies Inc.). The separation 
process was controlled by Agilent ChemStation, version B.04.02 extended by spectral module (Agilent 
Technologies Inc.). Mobile phase consisted of MeOH (HPLC grade, 70%) and H2O (HPLC-Milli-Q 
Grade, 30%). Conditions: Flow rate 1.0 mL/min, sample injection volume 20 μL, column temperature 
30 °C, detection wavelength 210 nm, monitor wavelength 270 nm. Retention times (tR) were measured 
in minutes. The dead time of the system (tD) was determined as the retention time of KI methanol 
solution. Capacity factors k for individual compounds were calculated according to the formula  
k = (tR − tD)/tD. Log k, calculated from the capacity factor k, is used as the lipophilicity index converted 
to log scale. 
3.5. Biological Assays 
3.5.1. Evaluation of in Vitro Antimycobacterial Activity 
Microdilution panel method. Tested strains M. tuberculosis H37Rv CNCTC My 331/88, M. kansasii 
Hauduroy CNCTC My 235/80 and M. avium ssp. avium Chester CNCTC My 80/72 were obtained from 
Czech National Collection of Type Cultures (CNCTC), National Institute of Public Health, Prague, 
Czech Republic. Culturing medium was Middlebrook 7H9 broth (Sigma-Aldrich) with the addition of 
glycerol (Sigma-Aldrich) and OADC supplement (Himedia, Mumbai, India). Isoniazid was used as 
standard. Tested compounds were dissolved and diluted in DMSO and mixed with growth media to final 
concentrations of 100, 50, 25, 12.5, 6.25, 3.125 and 1.5625 μg/mL. The final concentration of DMSO did 
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not exceed 1% (v/v) and did not affect the growth of mycobacteria. The cultures were grown in 
Middlebrook 7H9 medium at 37 °C in humid dark atmosphere. The antimycobacterial activity was 
determined using Alamar Blue colouring after 14 days of incubation as MIC (μg/mL). This evaluation 
was done in cooperation with Department of Clinical Microbiology, University Hospital in Hradec 
Králové, Czech Republic. 
3.5.2. Evaluation of in Vitro Antibacterial Activity 
Microdilution broth method [44]. Antibacterial evaluation was performed against bacterial strains 
from Czech Collection of Microorganisms (Brno, Czech Republic) (Staphylococcus aureus CCM 
4516/08, Escherichia coli CCM 4517, Pseudomonas aeruginosa CCM 1961) or clinical isolates from 
Department of Clinical Microbiology, University Hospital and Faculty of Medicine in Hradec Králové, 
Charles University in Prague, Czech Republic (Staphylococcus aureus H 5996/08-methicilin resistant 
(MRSA), Staphylococcus epidermidis H 6966/08, Enterococcus sp. J 14365/08, Klebsiella pneumoniae D 
11750/08, Klebsiella pneumoniae J 14368/08-ESBL positive). All strains were subcultured on Mueller-
Hinton agar (MHA) (Difco/Becton Dickinson, Detroit, MI, USA) at 35 °C and maintained on the same 
medium at 4 °C. The compounds were dissolved in DMSO, and the antibacterial activity was determined 
in Mueller-Hinton liquid broth (Difco/Becton Dickinson), buffered to pH 7.0. Controls consisted of 
medium and DMSO alone. The final concentration of DMSO in the test medium did not exceed 1% (v/v) 
of the total solution composition. The minimum inhibitory concentration (MIC), defined as 95% 
inhibition of bacterial growth as compared to control, was determined after 24 and 48 h of static 
incubation at 35 °C. The standards were neomycin, bacitracin, penicillin G, ciprofloxacin and 
phenoxymethylpenicilin. 
3.5.3. Evaluation of in Vitro Antifungal Activity 
Antifungal evaluation was performed using microdilution broth method [45] against 8 fungal strains 
(Candida albicans ATCC 44859, C. tropicalis 156, C. krusei E28, C. glabrata 20/I, Trichosporon asahii 
1188, Aspergillus fumigates 231, Absidia corymbifera 272 and Trichophyton mentagrophytes 445). 
Compounds were dissolved in DMSO and diluted in a twofold manner with RPMI 1640 medium  
with glutamine buffered to pH 7.0 (3-morpholinopropane-1-sulfonic acid). The final concentration  
of DMSO in the tested medium did not exceed 2.5% (v/v) of the total solution composition. Static 
incubation was performed in the dark and humid, at 35 °C for 24 and 48 h (respectively 72 and 120 h 
for Trichophyton mentagrophytes). The MIC was defined as 80% inhibition of control (50% IC for 
filament fungi). Drug-free controls were included. The standards were amphotericin B, voriconazole, 
nystatin and fluconazole. 
3.5.4. Antiviral Evaluation 
Antiviral activity in cell culture assessed by cytopathic effect (CPE) reduction assays with a broad 
panel of viruses [46–48]. The following viruses were examined on human embryonic lung fibroblast 
cells: herpes simplex virus type 1 (HSV-1); a thymidine kinase-deficient (TK−) HSV-1 KOS strain 
resistant to acyclovir; herpes simplex virus type 2 (HSV-2); vaccinia virus; human adenovirus type 2; 
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and vesicular stomatitis virus (VSV). The viruses examined on human cervix carcinoma HeLa cells 
were: VSV; Coxsackie B4 virus; and respiratory syncytial virus (RSV). African Green Monkey Vero 
cells were used to determine the antiviral effect on para-influenza-3 virus; reovirus-1; Sindbis virus; 
Coxsackie B4 virus and Punta Toro virus. Human influenza A/H1N1, A/H3N2 and B viruses were 
assessed on Madin-Darby canine kidney (MDCK) cells. Activity against human immunofeficiency virus 
(HIV) type 1 and type 2 was studied in human MT-4 lymphoblast cells. To perform the tests, the virus 
was added to semiconfluent cell cultures in 96-well plates and simultaneously serial dilutions of the test 
compounds were added. The plates were incubated until clear CPE was reached (typically 3–6 days). 
Microscopic scoring was then performed to determine the antiviral activity [expressed as 50% effective 
concentration (EC50)]. In the case of HIV-1, HIV-2 and influenza virus, virus-induced CPE was 
determined by the colorimetric formazan-based MTS cell viability assay. 
3.5.5. Study of Inhibition of Photosynthetic Electron Transport (PET) in Spinach Chloroplasts 
Chloroplasts were prepared from spinach (Spinacia oleracea L.) according to Masarovicova and 
Kralova [49]. The inhibition of photosynthetic electron transport (PET) in spinach chloroplasts was 
determined spectrophotometrically (Genesys 6, Thermo Electron Scientific Instruments, Madison, WI, 
USA), using an artificial electron acceptor 2,6-dichlorophenol-indophenol (DCPIP) according to 
Kralova et al. [50], and the rate of photosynthetic electron transport (PET) was monitored as  
a photoreduction of DCPIP. The measurements were carried out in phosphate buffer (0.02 mol/L,  
pH 7.2) containing sucrose (0.4 mol/L), MgCl2 (0.005 mol/L) and NaCl (0.015 mol/L). The chlorophyll 
content was 30 mg/L in these experiments and the samples were irradiated (~100 W/m2 with 10 cm 
distance) with a halogen lamp (250 W) using a 4 cm water filter to prevent warming of the samples 
(suspension temperature 22 °C). The studied compounds were dissolved in DMSO due to their limited 
water solubility. The applied DMSO concentration (up to 4%) did not affect the photochemical activity 
in spinach chloroplasts. The inhibitory efficiency of the studied compounds was expressed by IC50 
values, i.e., by molar concentration of the compounds causing 50% PET inhibition relative to the 
untreated control. The comparable IC50 value for a selective herbicide 3-(3,4-dichlorophenyl)-1,1-
dimethylurea (DCMU, Diuron®) was about 1.9 μmol/L. 
3.5.6. Study of Fluorescence of Aromatic Amino Acids in Spinach Chloroplasts 
The fluorescence emission spectra of aromatic amino acids (AAA) in spinach chloroplasts  
were recorded on fluorescence spectrophotometer F-2000 (Hitachi, Tokyo, Japan) using excitation 
wavelength λex = 275 nm for monitoring AAA fluorescence, excitation slit 20 nm and emission  
slit 10 nm. The samples were kept in the dark for 2 min before measuring. The phosphate buffer used 
for dilution of the chloroplast suspension was the same as described above. Due to low aqueous solubility 
the compounds were added to chloroplast suspension in DMSO solution. The DMSO concentration in 
all samples was the same as in the control (10%). The chlorophyll concentration in chloroplast 
suspension was 10 mg/L.  
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4. Conclusions 
We prepared thirty alkylamino pyrazinamide derivatives. We focused on modification of carboxamide 
moiety (formal N-alkylation) and introduction of an alkylamino substituent to position 3 of the pyrazine 
ring. According to the antimycobacterial assay results, the most favourable substitutions were N-methyl 
for the carboxamide moiety and long (C6-C8) alkylamino substituents in position 3. The most active 
compounds against M. tuberculosis H37Rv were 14–16 (MIC = 25 μg/mL) with log k = 0.876–1.359 
(log P = 1.21–2.05). The other compounds showed lower or no activity. Compound 8 was the most 
effective compound against Trichophyton mentagrophytes (MIC 62.5 μmol/L) in antifungal assays. 
None of tested compounds produce any significant antibacterial or antiviral activity. Prepared compounds 
were not toxic on HeLa and Vero cells. 
The studied compounds inhibited photosynthetic electron transport (PET) in spinach chloroplasts. 
The PET-inhibiting activity was strongly connected with the lipophilicity of the compounds. The  
PET-inhibiting activity of N-alkyl-3-chloropyrazine-2-carboxamides, 3-(alkylamino)-N-methyl- 
pyrazine-2-carboxamides as well as 3-(alkylamino)-N-methylpyrazine-2-carboxamides increased 
linearly with increasing lipophilicity of the compounds. On the other hand, the dependence of  
PET-inhibiting activity of 3-(alkylamino)-N-methylpyrazine-2-carboxamides on lipophilicity showed 
bilinear course, the optimum being compound 27 (R1 = R2 = C5H11). For effective PET inhibition longer 
alkyl chain in 3-(alkylamino) substituent in the molecule was more favourable than two shorter alkyl 
chains in N-alkyl-3-(alkylamino)pyrazine-2-carboxamides. The interaction of studied compounds with 
aromatic amino acids situated mainly in photosystem 2 was confirmed by fluorescence experiments. 
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